Entries by

XL-protein Signs Licensing Agreement with MSD Animal Health to Develop Biopharmaceuticals using its PASylation® Technology

12. February 2015 in /by

FREISING, GERMANY, February 12, 2015 – XL-protein GmbH, Germany, a privately owned biopharmaceutical company, announced today that they have entered into a license agreement with MSD Animal Health (known as Merck Animal Health in the USA and Canada) to develop PASylated biopharmaceuticals for use in animal health. This license agreement follows a research collaboration between […]

XL-protein and YEDA sign business collaboration agreement to commercialize PASylated interferon superagonist

21. October 2014 in /by

FREISING, GERMANY & REHOVOT, ISRAEL, October 21, 2014 – Yeda Research and Development Company Ltd., the technology transfer arm of the Weizmann Institute of Science, Israel, and XL-protein GmbH, Germany, a privately owned biopharmaceutical company, have signed a business collaboration agreement to commercialize a PASylated interferon superagonist – PAS-YNSα8 – which has been jointly developed […]

XL-protein announces publication of key scientific data on its PASylation® technology

30. August 2013 in /by

FREISING, GERMANY, August 30, 2013 – XL-protein GmbH announced today that key scientific data have been published in the journal Protein Engineering, Design & Selection (2013, Vol. 26, No. 8, pp. 489–501, 2013). The Open Access Publication “PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins” is also available […]

XL-protein and GENERIUM sign broad therapeutic license and collaboration agreement to develop PASylated therapeutics for the Russian Federation

26. June 2013 in /by

Freising, Germany & Moscow, Russia, June 25, 2013 XL-protein and GENERIUM announce the closing of a license and a collaboration agreement. Under these agreements, XL-protein will license a PASylated blood clotting factor and apply its proprietary PASylation® technology for plasma-half life extension to a cytokine, respectively, for use in the Russian Federation and Commonwealth of […]

XL-protein and Wacker Biotech produce a PASylated antibody fragment (Fab) with prolonged plasma half-life at more than four grams per liter culture in an E. coli expression system

18. April 2013 in /by

High Yield with ESETEC® and PASylation®: Wacker Biotech and XL-protein Produce More than Four Grams per Liter of Fab Antibody Fragment with Prolonged Plasma Half-Life Munich, Jena and Freising, April 18, 2013 – In the course of their collaboration, Wacker Biotech and XL-protein have produced record yields of a PASylated Fab antibody using WACKER’s E. […]

Wacker Biotech and XL-protein Sign Long-Term Cooperation Agreement to Produce PASylated Biopharmaceuticals

31. October 2012 in /by

Munich / Freising / Jena, October 30, 2012 Wacker Biotech GmbH and XL-protein GmbH are to collaborate more intensely on the production of PASylated therapeutic proteins. Today, the two companies announced the signature of an agreement to this effect. Through this collaboration, WACKER and its customers will gain access to XL-protein’s PASylation® platform. The PASylation® […]

XL-protein and Wacker demonstrate high-yield production of PASylated biopharmaceuticals using ESETEC®

11. June 2012 in /by

Munich / Jena, June 11, 2012 – Wacker Biotech and XL-protein have successfully completed a feasibility study on the produc­tion of PASylated therapeutic proteins using WACKER’s ESETEC® E. coli secretion technology. In the study, WACKER technology was used to investigate the production of a PASylat­ed human growth hormone as model protein. WACKER devel­oped a cell […]

XL-protein announces in vitro and in vivo data for its PASylated hGH

23. September 2011 in /by

FREISING, GERMANY, September 23, 2011 – XL-protein GmbH, a German biotech company specialised in the development of biopharmaceuticals with extended plasma half-life, announced today preclinical in vitro and in vivo data for its xl020 PAS-hGH program. The xl020 data demonstrate XL-protein’s ability to furnish an approved biological drug with improved in vivo stability and plasma […]

European patent granted for XL-protein’s PASylation® technology

17. March 2011 in /by

FREISING, GERMANY, MARCH 17th, 2011 – XL-protein GmbH, a German biotech company that specialises in the development of biopharmaceuticals with extended plasma half-life, today announced that the European Patent Office granted a core patent (EP2173890) for XL-protein’s PASylation® technology. Beside the granted PASylation® EP patent, several other corresponding national patent applications are currently processed worldwide. […]

Phylogica collaborates with XL-protein on inflammation Program

13. January 2011 in /by

XL-protein Collaborates with Phylogica on Inflammation Program PERTH, AUSTRALIA, January 13, 2011 – Phylogica Ltd (ASX: PYC), a leading Australian-based drug discovery company, announced today an alliance with XL-protein GmbH, a German-based biotech company that specialises in extending the circulation half-life of biopharmaceuticals. Through this alliance, Phylogica gains access to a unique modification technology that […]